Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/332"

Predicate	Value (sorted: none)
rdf:type	?:Evidence
rdf:type	?:Item
rdfs:label	"evidence_1539"
?:Evidence_type	?:EV_CT_PK_Genotype
?:Evidence_enzyme_system	""
dc:creator	"boycer"
dc:date	"12172009"
?:content	"route of administration: oral study duration: single dose of 100 mg sertraline population: 12 healthy Chinese male, non-smokers tested for known CYP450 polymorphisms? Patients were genotyped for CYP2C19 polymorphisms and also phenotyped using the omeprazole/5-hydroxy-omeprazole metabolic ratio. 6 extensive metabolizers (EM) and 6 poor metabolizers (PM) were chosen using stratified random selection from a pool of 66 EMs and 11 PMs. ages: 19 - 22 years description: The poor metabolizers had a 41% increase in sertraline AUC(0-inf) (983.6 � 199.3 micg � h/L versus 697.6 � 133.0 mcg � h/L; P < .05) and a 51% increase in sertraline terminal elimination half-life (t_1/2) (35.5 � 5.6 hours 2 versus 23.5 � 4.4 hours; P < .01) compared with extensive metabolizers. The oral clearance (CL_oral) of sertraline in poor metabolizers was significantly lower than that in extensive metabolizers (105.3 � 19.4 L/h versus 148.4 � 28.6 L/h; P < .05). The AUC0-144 and Cmax of desmethylsertraline in poor metabolizers were significantly lower than the values in extensive metabolizers (627.6 � 203.8 �g � h/L versus 972.1 � 270.3 �g � h/L; P < .05; 23.6 � 6.5 nmol/L versus 32.4 � 8.2 nmol/L; P < .01; respectively). In addition, desmethylsertraline Tmax (time to reach Cmax) in poor metabolizers was markedly higher than that in extensive metabolizers (70.0 � 24.5 hours versus 26.4 � 5.4 hours; P < .01)."
rdfs:seeAlso	?:11452243

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl

The resource appears as object in one triple:

{ sertraline_is_not_substrate_of_cyp2c19, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1539 }

Context graph